Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform
Jiemei Yu, Yuanhui Fu, Yanpeng Zheng, Xianglei Peng, Jinsheng He · 2026
Read Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform by Jiemei Yu, Yuanhui Fu, Yanpeng Zheng, Xianglei Peng, Jinsheng He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13541641.txt.
Description
Yu and colleagues review live-attenuated vaccines against respiratory syncytial virus, the leading cause of severe chest infections in small children. It causes millions of illnesses and around a hundred thousand deaths under five each year worldwide. Older children past six months still lack any approved vaccine. Weakened-virus designs must walk a line between too feeble to protect and too strong to be safe, and early vaccine history left a shadow of enhanced disease. Their 2026 review tracks how reverse genetics changed the craft.
By editing the viral genome deliberately, developers can now tune weakening precisely and stack safeguards. Trials in children who have never met the virus show no sign of the vaccine-enhanced respiratory disease that haunted the field. The authors weigh newer platforms honestly: shots that protect newborns through their mothers fade within the first year.
Catalog record
| CREATOR | Jiemei Yu, Yuanhui Fu, Yanpeng Zheng, Xianglei Peng, Jinsheng He |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |